


AMENDMENTS TO THE CLAIMS

1. (Original) A compound according to formula I



wherein the fused rings A, B, C and D are independently saturated or fully or partially unsaturated;

the bond between C-17 and C-20 is depicted with a full and a dotted line to indicate that said bond can be a single or a double bond;

wherein R1 is hydrogen, halogen, a lipophilic group, $-(Z)_n-(NR-Z)_p-N(R)_2$ or

$C(O)-(Z)_n-(NR-Z)_p-N(R)_2$, wherein n is 0 or 1 and p is an integer from 1 and 5;

each Z independently represents straight or branched hydrocarbon diradical, optionally

substituted with C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, hydroxy, alkoxy, amino,

C_{1-6} aminoalkoxy, C_{1-6} aminoalkyl, C_{1-6} aminoalkylaminocarbonyl,

C_{1-6} alkyl/ C_{3-8} cycloalkyl or C_{1-6} alkylheteroaryl;

each R independently represents hydrogen or C_{1-6} alkyl, C_{1-6} aminoalkyl,

C₁₋₆aminoalkoxy or C₁₋₆aminoalkylaminocarbonyl, all of which are optionally substituted with alkyl or C₁₋₆aminoalkyl;

provided that at least one Z is substituted with C₁₋₆ alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, hydroxy, alkoxy, C₁₋₆aminoalkoxy, C₁₋₆aminoalkyl, C₁₋₆aminoalkylaminocarbonyl,

C₁₋₆alkylC₃₋₈cycloalkyl or C₁₋₆alkylheteroaryl, or at least one R is different from hydrogen;

R₂ represents halogen, C₁₋₄alkyl, optionally substituted with COOH; C₁₋₄alkoxy, -COOH,

-(Z)_n-(NR-Z)_p-N(R)₂ or C(O)-(Z)_n-(NR-Z)_p-N(R)₂;

R₃ represents hydrogen halogen or O-R₁₉, wherein R₁₉ represents hydrogen, -SO₃,

C₁₋₆alkyl, C₁₋₆acyl or -(Z)_n-(NR-Z)_p-N(R)₂;

each of R₄, R₇, R₈, R₁₁, R₁₂, R₁₃, R₁₆ and R₁₇ independently represent hydrogen, halogen, hydroxy, -OSO₃, -O-acyl, -(Z)_n-(NR-Z)_p-N(R)₂ or

C(O)-(Z)_n-(NR-Z)_p-N(R)₂;

R₁₀ represents hydrogen, methyl, halogen, hydroxy, -OSO₃, -O-acyl, -(Z)_n-(NR-Z)_p-N(R)₂ or

C(O)-(Z)_n-(NR-Z)_p-N(R)₂;

each of R₅, R₆, R₉, R₁₄, R₁₅ and R₁₈ independently represent hydrogen or methyl or are each independently absent when one of the fused rings, A, B, C and D are unsaturated so as to complete the valency of the carbon atom at that site;

provided that at least one, and not more than three of R₁, R₂, R₄, R₇, R₈, R₁₀, R₁₁, R₁₂, R₁₃,

R₁₆ and R₁₇ is -(Z)_n-(NR-Z)_p-N(R)₂ or

C(O)-(Z)_n-(NR-Z)_p-N(R)₂;

provided that the compound is not

3β-hydroxy-6β-(2-dimethylaminoethyl)amino-5α-stigmastane,


3 β -hydroxy-6 β -(2-diethylaminoethyl)amino-5 α -stigmastane,
3 β -hydroxy-6 β -(3-dimethylaminopropyl)amino-5 α -stigmastane,
3 β -hydroxy-6 α -(2-diethylaminoethyl)amino-5 α -stigmastane,
3 β -hydroxy-6 β -(2-diethylaminoethyl)amino-5 α -cholestane,
3 β -hydroxy-6 β -(2-diethylaminoethyl)amino-5 α -cholestane,
3 β -hydroxy-6 β -(3-dimethylaminopropyl)amino-5 α -cholestane,
3 β -hydroxy-6 α -(2-diethylaminoethyl)amino-5 α -cholestane,
20-(γ -diethylaminopropyl)-amino-5 α -pregnan-3 β -ol,
20-(β -diethylaminoethyl)-amino-5 α -pregnan-3 β -ol,
20-(β -dimethylaminoethyl)-amino-5 α -pregnan-3 β -ol,
20-(β -dimethylaminoethyl)-aminopregn-5-en-3 β -ol,
20-(β -diethylaminoethyl)-aminopregn-5-en-3 β -ol,
N(β -diethylaminoethyl)-3 α ,7 α ,12 α -trihydroxy-5 β -cholan-24-amide,
N(β -diethylaminoethyl)-3 α ,12 α -dihydroxy-5 β -cholan-24-amide,
N(β -diethylaminoethyl)-3 α ,7 α ,12 α -trihydroxy-5 β -cholan-24-amine, or
N(β -diethylaminoethyl)-3 α ,12 α -dihydroxy-5 β -cholan-24-amine, and
and pharmaceutically acceptable salts or esters thereof.

2. (Original) A compound according to claim 1, wherein R₂ represents $-(Z)_n-(NR-Z)_p-$
N(R)₂ or C(O)-(Z)_n-(NR-Z)_p-N(R)₂.


3. (Original) A compound according to claim 1, wherein R7, R11 and/or R16 represents –
 $(Z)_n-(NR-Z)_p-N(R)_2$ or $C(O)-(Z)_n-(NR-Z)_p-N(R)_2$.
4. (Original) A compound according to claim 1, wherein R1 represents a lipophilic group.
5. (Original) A compound according to claim 1, wherein R1 is selected from the group consisting of straight or branched, saturated or unsaturated C_{1-10} alkyl, aryl, C_{3-8} cycloalkyl, aralkyl with 1-10 carbon atoms in the alkyl moiety, C_{1-10} alkylaryl, C_{1-10} alkyl- C_{3-8} cycloalkyl, C_{1-10} alkoxy and heteroaryl.
6. (Currently Amended) A compound according to ~~any of claims 1-5~~ claim 1, wherein R19 represents
 C_{1-6} alkyl or C_{1-6} acyl.
7. (Previously Presented) A compound according to claim 1, wherein R7, R11 and/or R16 represents OH
8. (Currently Amended) A compound according to ~~any of claims 1-5~~ claim 1, wherein R11 represents
–OSO₃.

9. (Currently Amended) A compound according to ~~any of claims 1-5~~ claim 1, wherein R11 represents -O-acyl.

10. (Currently Amended) A compound according to claim 1 which has the general formula Ia



or which has the general formula Ib



11. (Cancelled)

12. (Currently Amended) A compound according to claim 10 or 11, wherein R2 represents –
(Z)_n-(NR-Z)_p-N(R)₂ or C(O)-(Z)_n-(NR-Z)_p-N(R)₂.

13. (Original) A compound according to claim 12, wherein R7 and R11 are both hydroxy.


14. (Original) A compound according to claim 12, wherein R11 and R16 are both hydroxy.

15. (Original) A compound according to claim 12, wherein R3 is –OR19, wherein R19 is C₁-
6alkyl or C₁-6acyl.

16. (Cancelled)

17. (Original) A compound according to claim 12, wherein R1 is a straight or branched,
saturated or unsaturated C₁₋₁₀hydrocarbon.

18. (Original) A compound according to claim 12, wherein R1 is a moiety of formula II



wherein the carbon-carbon bond denoted “*” is a single or double bond.

19. (Currently Amended) A compound according to ~~claims 10 or 11~~ claim 10, wherein R11 represents

$-(Z)_n-(NR-Z)_p-N(R)_2$ or $C(O)-(Z)_n-(NR-Z)_p-N(R)_2$.


20. (Original) A compound according to claim 19, wherein R2 is C₁₋₄alkyl, optionally substituted with COOH, C₁₋₄alkoxy or COOH.

21. (Original) A compound according to claim 19, wherein R3 is O-R19, wherein R19 represents C₁₋₆alkyl or C₁₋₆acyl.

22. (Cancelled)




23. (Original) A compound according to claim 19, wherein R1 is a straight or branched, saturated or unsaturated C₁₋₁₀hydrocarbon.




24. (Original) A compound according to claim 19, wherein R1 is a moiety of formula II



wherein the carbon-carbon bond denoted "*" is a single or double bond.

25. (Currently Amended) A compound according to ~~any one of claims 1, 10 or 11~~ claim 1,
wherein R2 and/or R11 represents a moiety of the formula VIII, IX, X, XI, XII or XIII





26. (Original) A compound according to claim 1 selected from the list consisting of

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-17R,20S,24,25-tetrahydrofusid-21-amide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-11-desoxy -17R,20S,24,25-tetrahydrofusid-
 21-amide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-16-desacetoxy-17R,20S,24,25-
 tetrahydrofusid-21-amide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-13(17)-en-17,20,24,25-tetrahydrofusidan-21-
 carboxamide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-3 β -desacetoxo-17R,20S,24,25-tetrahydrofusid-21-amide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-9(11)-en-17R,20S,24,25-tetrahydrofusid-21-amide,

24-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-3 α -hydroxy-5 β -cholan-24-amide,

22-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-23,24-bisnor-5-cholenic-22-amide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-fusid-21-amide,

21-N-{3'-[bis(3'-aminopropyl)amino]propyl}-fusid-21-amide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-3-OSO₃-11-desoxy-17,20,24,25-tetrahydrofusid-21-amide,

21-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-11-desoxy-16-desacetoxo-17S,20,24,25-tetrahydrofusid-21-amide,

21-N-{3'-[bis(3'-aminopropyl)amino]propyl}-17R,20S,24,25-tetrahydrofusid-21-amide,

22-N-{3'-[bis(3'-aminopropyl)amino]propyl}-23,24-bisnor-5-cholenic-22-amide,

21-N-{3'-[bis(3'-aminopropyl)amino]propyl}-3-OAc-17R,20S,24,25-tetrahydrofusid-21-amide,

21-N-{3'-[bis(3'-aminopropyl)amino]propyl}-3-OSO₃-11-desoxy-17,20,24,25-tetrahydrofusid-21-amide,

21-N-{3'-[bis(3'-aminopropyl)amino]propyl}-11-desoxy-16-desacetoxo-17S,20,24,25-tetrahydrofusid-21-amide,

3-N-{2'-[bis(2'-aminoethyl)amino]ethyl}-fusidic acid,

21-N-{3'-[(3'-aminopropyl)(methyl)amino]propyl}-17R,20S,24,25-tetrahydrofusid-21-amide,

21-N-{3'-[(3'-aminopropyl)(methyl)amino]propyl}-11-desoxy-17R,20S,24,25-tetrahydrofusid-21-amide,

21-N-{3'-[(3'-aminopropyl)(methyl)amino]propyl}-16-desacetoxy-17R,20S,24,25-tetrahydrofusid-21-amide,

24-N-{3'-[(3'-aminopropyl)(methyl)amino]propyl}-3 α -hydroxy-5 β -cholan-24-amide,

21-N-{3'-[(3'-aminopropyl)(methyl)amino]propyl}-11desoxy-16-desacetoxy-17R,20S,24,25-tetrahydrofusid-21-amide,

3-N-{3'-[bis(3'-aminopropyl)amino]propyl}-}-fusidic acid,

3-N-{3'-[(3'-aminopropyl)(methyl)amino]propyl}-fusidic acid.

27. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1, optionally together with a pharmaceutically acceptable excipient or vehicle, and optionally other therapeutically active agents.

28. - 32. (Cancelled)

33. (Currently Amended) A method of preventing or treating a bacterial infection, the method comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

Application No. 10/509,911
Amendment dated January 31, 2008
Second Preliminary Amendment

Docket No.: 3893-0200PUS2

34. - 36. (Cancelled)